Invention Grant
- Patent Title: Bridged bicyclic inhibitors of menin-MLL and methods of use
-
Application No.: US16927844Application Date: 2020-07-13
-
Publication No.: US11555041B2Publication Date: 2023-01-17
- Inventor: Tao Wu , Liansheng Li , Yi Wang , Pingda Ren , Jolanta Grembecka , Tomasz Cierpicki , Szymon Klossowski , Jonathan Pollock , Dmitry Borkin
- Applicant: Kura Oncology, Inc. , The Regents of The University of Michigan
- Applicant Address: US CA San Diego; US MI Ann Arbor
- Assignee: Kura Oncology, Inc.,The Regents of The University of Michigan
- Current Assignee: Kura Oncology, Inc.,The Regents of The University of Michigan
- Current Assignee Address: US CA San Diego; US MI Ann Arbor
- Agency: Wilson Sonsini Goodrich & Rosati
- Main IPC: C07D495/04
- IPC: C07D495/04 ; A61K31/445 ; A61P35/02
Abstract:
The present disclosure provides compounds of Formula (I-A) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Public/Granted literature
- US20210107917A1 BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE Public/Granted day:2021-04-15
Information query
